Hiv infection among people who inject drugs: The challenge of racial/ethnic disparities

American Psychologist

Volumn 68, Issue 4, 2013, Pages 274-285

  Jarlais, Don C Des ^a   McCarty, Dennis ^b   Vega, William A ^c   Bramson, Heidi ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Health disparities; HIV; Injection drug use

Indexed keywords

ADDICTION; ARTICLE; COMORBIDITY; ETHNOLOGY; EVIDENCE BASED PRACTICE; FEMALE; HEALTH DISPARITY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION; MALE; METHODOLOGY; NEGRO; STANDARD; STATISTICS;

AFRICAN CONTINENTAL ANCESTRY GROUP; COMORBIDITY; EVIDENCE-BASED PRACTICE; FEMALE; HEALTH STATUS DISPARITIES; HISPANIC AMERICANS; HIV INFECTIONS; HUMANS; INJECTIONS; MALE; SUBSTANCE-RELATED DISORDERS;

EID: 84880984895     PISSN: 0003066X     EISSN: None     Source Type: Journal    
DOI: 10.1037/a0032745     Document Type: Article

References (111)

1. Barry, C. L.,&Huskamp, H. A. (2011). Moving beyond parity-mental health and addiction care under the ACA. New England Journal of Medicine, 365, 973-975. doi:10.1056/NEJMp1108649
2. Berridge, V. (2009). Heroin prescription and history. New England Journal of Medicine, 361, 820-821. doi:10.1056/NEJMe0904243
3. Beyrer, C., Razak, M. H., Lisam, K., Chen, J.,&Lui, W. (2000). Overland heroin trafficking routes and HIV-1 spread in South and Southeast Asia. AIDS, 14, 75-83. doi:10.1097/00002030-200001070-00009
4. Blanken, P., van den Brink, W., Hendriks, V. M., Huijsman, I. A., Klous, M. G., Rook, E. J., . . . Van Ree, J. M. (2010). Heroin-assisted treatment in the Netherlands: History, findings, and international context. European Neuropsychopharmacology, 20, S105-S158. doi:10.1016/S0924- 977X(10)70001-8
5. Blower, S. M., Gershengorn, H. B.,&Grant, R. M. (2000). A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science, 287, 650-654. doi:10.1126/science.287.5453.650
6. Booth, R. E., Crowley, T. J.,&Zhang, Z. (1996). Substance abuse treatment entry, retention and effectiveness: Out-of-treatment opiate injection drug users. Drug and Alcohol Dependence, 42, 11-20. doi: 10.1016/0376-8716(96)01257-4
7. Booth, R. E., Des Jarlais, D. C.,&Friedman, S. R. (2009). Reflections on 25 years of HIV and AIDS research among drug abusers. Journal of Drug Issues, 39, 209-221. doi:10.1177/002204260903900116
8. Booth, R. E., Kwiatkowski, C. F.,&Stephens, R. C. (1998). Effectiveness of HIV/AIDS interventions on drug use and needle risk behaviors for out-of-treatment injection drug users. Journal of Psychoactive Drugs, 30, 269-278. doi:10.1080/02791072.1998.10399702
9. Bowen, E. A. (2012). Clean needles and bad blood: Needle exchange as morality policy. Journal of Sociology and Social Welfare, 39, 121-141.
10. Branson, B. M., Handsfield, H. H., Lampe, M. A., Janssen, R. S., Taylor, A. W., Lyss, S. B.,&Clark, J. E. (2006). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. Morbidity and Mortality Weekly Report (MMWR), 55(RR 14), 1-17.
11. Brown, L. S., Kritz, S. A., Goldsmith, R. J., Bini, E. J., Robinson, J., Alderson, D.,&Rotrosen, J. (2007). Health services for HIV/AIDS, Hepatitis C virus, and sexually transmitted infections in substance abuse treatment programs. Public Health Reports, 122, 441-451.
12. Buck, J. A. (2011). The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Affairs, 30, 1402-1410. doi:10.1377/hlthaff.2011.0480
13. Canada v. PHS Community Services Society, 2011 S.C.C. 44, [2011] 3 S.C.R. 134. Retrieved from http://scc.lexum.org/decisia-scc-csc/scccsc/ scc-csc/en/item/7960/index.do
14. Carlson, R. G., Singer, M., Stephens, R. C.,&Sterk, C. E. (2009).Reflections on 40 years of ethnographic drug abuse research: Implications for the future. Journal of Drug Issus, 39, 57-70. doi:10.1177/002204260903900106
15. Celentano, D. D., Galai, N., Sethi, A. K., Shah, N. G., Strathdee, S. A., Vlahov, D.,&Gallant, J. E. (2001). Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS, 15, 1707-1715. doi:10.1097/00002030-200109070-00015
16. Celentano, D. D., Vlahov, D., Cohn, S., Shadle, V. M., Obasanjo, O.,&Moore, R. D. (1998). Self-reported antiretroviral therapy in injection drug users. JAMA: Journal of the American Medical Association, 280, 544-546. doi:10.1001/jama.280.6.544
17. Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., . . . Fleming, T. R. (2011). Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine, 365, 493-505. doi:10.1056/NEJMoa1105243
18. Controlled Drugs and Substances Act, S.C. 1996, c.19. Retrieved from http://laws-lois.justice.gc.ca/eng/acts/C-38.8/
19. Cooper, H. L. F., Des Jarlais, D. C., Ross, Z., Tempalski, B., Bossak, B.,&Friedman, S. R. (2011). Spatial access to syringe exchange programs and pharmacies selling over-the-counter syringes as predictors of drug injectors' use of sterile syringes. American Journal of Public Health, 101, 1118-1125. doi:10.2105/AJPH.2009.184580
20. Cooper, H. L., Des Jarlais, D. C., Tempalski, B., Bossak, B., Ross, Z.,&Friedman, S. R. (2012). Drug-related arrests rates and spatial access to syringe exchange programs in New York City health districts: Combined effects on the risk of injection-related infections among injectors. Health and Place, 18, 218-228. doi:10.1016/j.healthplace.2011.09.005
21. Courtwright, D., Joseph, H.,&Des Jarlais, D. (1989). Addicts who survived: An oral history of narcotic use in America, 1923-1965. Knoxville, TN: University of Tennessee Press.
22. Coyle, S. L. (1993). The NIDA HIV counseling and education intervention model: Intervention manual. (NIH Publication No. 93-3580). Rockville, MD: National Institute on Drug Abuse.
23. Cunningham, W. E., Markson, L. E., Andersen, R. M., Crystal, S. H., Fleishman, J. A., Golin, C., . . . Wenger, N. S. (2000). Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. HCSUS Consortium. HIV Cost and Services Utilization. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 25, 115-123. doi:10.1097/00126334-200010010-00005
24. D'Aquila, R. T., Peterson, L. R., Williams, A. B.,&William, A. E. (1989). Race/ethnicity as a risk factor for HIV-1 infection among Connecticut intravenous drug users. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 2, 503-513.
25. Das, M., Chu, P. L., Santos, G.-M., Scheer, S., Vittinghoff, E., McFarland, W.,&Colfax, G. N. (2010). Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One, 5, e11068. doi:10.1371/journal.pone.0011068
26. DeBeck, K., Kerr, T., Bird, L., Zhang, R., Marsh, D., Tyndall, M. W., . . . Wood, E. (2011). Injection drug use cessation and use of North America's first medically supervised safer injecting facility. Drug and Alcohol Dependence, 113, 172-176. doi:10.1016/j.drugalcdep.2010.07 .023
27. Degenhardt, L., Mathers, B., Vickerman, P., Rhodes, T., Latkin, C.,&Hickman, M. (2010). Prevention of HIV infection for people who inject drugs: Why individual, structural, and combination approaches are needed. The Lancet, 376, 285-301. doi:10.1016/S0140- 6736(10)60742-8
28. Des Jarlais, D. C., Arasteh, K.,&Gwadz, M. (2010). Increasing HIV prevention and care for injecting drug users. The Lancet, 375, 961-963. doi:10.1016/S0140-6736(10)60314-5
29. Des Jarlais, D. C., Arasteh, K., Hagan, H., McKnight, C., Perlman, D. C.,&Friedman, S. R. (2009). Persistence and change in disparities in HIV infection among injection drug users in New York City after large-scale syringe exchange programs. American Journal of Public Health, 99(Suppl. 2), S445-S451. doi:10.2105/AJPH.2008.159327
30. Des Jarlais, D. C., Arasteh, K., McKnight, C., Hagan, H., Perlman, D. C., Torian, L., . . . Friedman, S. R. (2010). HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: The importance of transmission behaviors. Drug and Alcohol Dependence, 109, 154-160. doi:10.1016/j.drugalcdep.2009.12.028
31. Des Jarlais, D. C., Cooper, H., Bramson, H., Deren, S., Hatzakis, A.,&Hagan, H. (2012). Racial and ethnic disparities and implications for the prevention of HIV among persons who inject drugs. Current Opinion in HIV and AIDS, 7, 354-361. doi:10.1097/COH.0b013e328353d990
32. Des Jarlais, D. C., Friedmann, P., Hagan, H.,&Friedman, S. R. (1996). The protective effect of AIDS-related behavioral change among injection drug users: A cross-national study. American Journal of Public Health, 86, 1780-1785. doi:10.2105/AJPH.86.12.1780
33. Des Jarlais, D. C., Marmor, M., Friedmann, P., Titus, S., Aviles, E., Deren, S., . . . Monterroso, E. (2000). HIV incidence among injection drug users in New York City, 1992-1997: Evidence for a declining epidemic. American Journal of Public Health, 90, 352-359. doi:10.2105/AJPH.90.3.352
34. Des Jarlais, D. C., Marmor, M., Paone, D., Titus, S., Shi, Q., Perlis, T., . . . Friedman, S. R. (1996). HIV incidence among injecting drug users in New York City syringe-exchange programmes. The Lancet, 348, 987-991. doi:10.1016/S0140-6736(96)02536-6
35. Des Jarlais, D. C., Perlis, T., Arasteh, K., Torian, L. V., Beatrice, S., Milliken, J.,&Friedman, S. R. (2005). HIV incidence among injection drug users in New York City, 1990 to 2002: Use of serologic test algorithm to assess expansion of HIV prevention services. American Journal of Public Health, 95, 1439-1444. doi:10.2105/AJPH.2003 .036517
36. Des Jarlais, D. C., Perlis, T., Friedman, S. R., Chapman, T., Kwok, J., Rockwell, R., . . . Monterroso, E. (2000). Behavioral risk reduction in a declining HIV epidemic: Injection drug users in New York City, 1990-1997. American Journal of Public Health, 90, 1112-1116. doi: 10.2105/AJPH.90.7.1112
37. Drucker, E. (2006). Insite: Canada's landmark safe injecting program at risk. Harm Reduction Journal, 3, 24. doi:10.1186/1477-7517-3-24
38. Ferri, M., Davoli, M.,&Perucci, C. A. (2011). Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database of Systematic Reviews, 2011(12), 1-51. doi:10.1002/14651858.CD003410.pub3
39. Fischer, B., Rehm, J., Kirst, M., Casas, M., Hall, W., Krausz, M., . . . van Rhee, J. M. (2002). Heroin-assisted treatment as a response to the public health problem of opiate dependence. European Journal of Public Health, 12, 228-234. doi:10.1093/eurpub/12.3.228
40. Friedman, S. R., Curtis, R., Neaigus, A., Jose, B.,&Des Jarlais, D. C. (1999). Social networks, drug injectors' lives, and HIV/AIDS. New York, NY: Kluwer Academic.
41. Friedman, S. R., Des Jarlais, D. C.,&Sterk, C. E. (1990). AIDS and the social relations of intravenous drug users. Milbank Quarterly, 68, 85-110. doi:10.2307/3350177
42. Galai, N., Vlahov, D., Bareta, J. C., Wang, C., Cohn, S.,&Sterling, T. R. (2005). Prognostic factors for survival differ according to CD4 cell count among HIV infected injection drug users: Pre-HAART and HAART eras. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 38, 74-81. doi:10.1097/00126334-200501010-00014
43. Gebo, K. A., Fleishman, J. A., Conviser, R., Reilly, E., Korthuis, P. T., Moore, R., . . . Christopher, M. W. (2005). Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 38, 96-103. doi:10.1097/00126334-200501010- 00017
44. Guardino, V., Des Jarlais, D. C., Arasteh, K., Johnston, R., Purchase, D., Solberg, A., . . . Lentine, D. (2010). Syringe exchange programs- United States, 2008. Morbidity and Mortality Weekly Report (MMWR), 59(45), 1488-1491.
45. Guerrero, E.,&Andrews, C. M. (2011). Cultural competence in outpatient substance abuse treatment: Measurement and relationship to wait time and retention. Drug and Alcohol Dependence, 119, e13-e22. doi: 10.1016/j.drugalcdep.2011.05.020
46. Guerrero, E. G.,&Cederbaum, J. A. (2011). Adoption and utilization of sexually transmitted infections testing in outpatient substance abuse treatment facilities serving high risk populations in the U.S. International Journal of Drug Policy, 22, 41-48. doi:10.1016/j.drugpo.2010 .09.005
47. Hagan, H., Des Jarlais, D. C., Purchase, D., Reid, T.,&Friedman, S. R. (1991). The Tacoma syringe exchange. Journal of Addictive Diseases, 10, 81-88. doi:10.1300/J069v10n04_06
48. Hagan, H., McGough, J. P., Thiede, H., Weiss, N. S., Hopkins, S.,&Alexander, E. R. (1999). Syringe exchange and risk of infection with hepatitis B and C viruses. American Journal of Epidemiology, 149, 203-213. doi:10.1093/oxfordjournals.aje.a009792
49. Hagan, H., Pouget, E. R.,&Des Jarlais, D. C. (2011). A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. Journal of Infectious Diseases, 204, 74-83. doi:10.1093/infdis/jir196
50. Hall, H. I., McDavid, K., Ling, Q.,&Sloggett, A. (2006). Determinants of progression to AIDS or death after HIV diagnosis, United States, 1996 to 2001. Annals of Epidemiology, 16, 824-833. doi:10.1016/j .annepidem.2006.01.009
51. Hallfors, D. D., Iritani, B. J., Miller, W. C.,&Bauer, D. J. (2007). Sexual and drug behavior patterns and HIV and STD racial disparities: The need for new directions. American Journal of Public Health, 97, 125- 132. doi:10.2105/AJPH.2005.075747
52. Heimer, R., Kaplan, E. H., Khoshnood, K., Jarlwala, R.,&Cadman, E. C. (1993). Needle exchange decreases the prevalence of HIV-1 proviral DNA in returned syringes in New Haven, Connecticut. American Journal of Medicine, 95, 214-220. doi:10.1016/0002-9343(93)90263-O
53. Hicks, P. L., Mulvey, K. P., Chander, G., Fleishman, J. A., Josephs, J. S., Korthuis, P. T., . . . HIVResearch Network. (2007). The impact of illicit drug use and substance abuse treatment on adherence to HAART. AIDS Care, 19, 1134-1140. doi:10.1080/09540120701351888
54. Hoffman, K. A., Ford, J. H., Choi, D., Gustafson, D.,&McCarty, D. (2008). Replication and sustainability of improved access and retention within the Network for the Improvement of Addiction Treatment. Drug and Alcohol Dependence, 98, 63-69. doi:10.1016/j.drugalcdep.2008.04 .016
55. Hoffman, K. A., Ford, J. H., Tillotson, C. J., Choi, D.,&McCarty, D. (2011). Days to treatment and early retention among patients in treatment for alcohol and drug disorders. Addictive Behaviors, 36, 643-647. doi:10.1016/j.addbeh.2011.01.031
56. Institute of Medicine. (2003). Unequal treatment: Confronting racial and ethnic disparities in health care. Washington, DC: National Academies Press.
57. Institute of Medicine. (2006). Preventing HIV infection among injecting drug users in high risk countries. Washington, DC: National Academies Press.
58. Kerr, T., Montaner, J. S. G.,&Wood, E. (2010). Science and politics of heroin prescription. The Lancet, 375, 1849-1850. doi:10.1016/S0140- 6736(10)60544-2
59. Kerr, T., Tyndall, M. W., Lai, C., Montaner, J. S. G.,&Wood, E. (2006). Drug-related overdoses within a medically supervised safer injection facility. International Journal of Drug Policy, 17, 436-441. doi: 10.1016/j.drugpo.2006.05.008
60. Kerr, T., Tyndall, M. W., Li, K., Montaner, J.,&Wood, E. (2005). Safer injection facility use and syringe sharing in injection drug users. The Lancet, 366, 316-318. doi:10.1016/S0140-6736(05)66475-6
61. Koblin, B. A., McCusker, J., Lewis, B.,&Sullivan, J. (1990). Racial/ ethnic differences in HIV-1 seroprevalence and risky behaviors among intravenous drug users in a multisite study. American Journal of Epidemiology, 132, 837-846.
62. Korthuis, P. T., Fiellin, D. A., Fu, R., Lum, P. J., Altice, F. L., Sohler, N., . . . McCarty, D. (2011). Improving adherence to HIV quality of care indicators in persons with opioid dependence: The role of buprenorphine. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 56(Suppl. 1), S83-S90. doi:10.1097/QAI.0b013e31820bc9a5
63. Korthuis, P. T., Tozzi, M. J., Nandi, V., Fiellin, D. A., Weiss, L., Egan, J. E., . . . Altice, F. L. (2011). Improved quality of life for opioiddependent patients receiving buprenorphine treatment in HIV clinics. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 56(Suppl. 1), S39-S45. doi:10.1097/QAI.0b013e318209754c
64. Lambert, E. Y.,&Wiebel, W. W. (1990). Introduction. In E. Y. Lambert (Ed.), The collection and interpretation of data from hidden populations (NIDA Research Monograph 98, pp. 1-3). Rockville, MD: National Institute on Drug Abuse.
65. Mark, T. L., Levit, K. R., Coffey, R. M., McKusick, D., Harwood, H. J., King, E., . . . Ryan, K. (2007). National expenditures for mental health services and substance abuse treatment: 1993-2003 (SAMHSA Publication No. SMA 07-4227). Rockville, MD: Substance Abuse and Mental Health Services Administration.
66. Mark, T. L., Levit, K. R., Vandivort-Warren, R., Buck, J. A.,&Coffey, R. M. (2011). Changes in US spending on mental health and substance abuse treatment, 1986-2005, and implications for policy. Health Affairs, 30, 284-292. doi:10.1377/hlthaff.2010.0765
67. Marshall, B. D. L., Milloy, M. J., Wood, E., Montaner, J. S. G.,&Kerr, T. (2011). Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: A retrospective population-based study. The Lancet, 377, 1429-1437. doi: 10.1016/S0140-6736(10)62353-7
68. Mathers, B. M., Degenhardt, L., Ali, H., Wiessing, L., Hickman, M., Mattick, R. P., Strathee, S. A. (2010). HIV prevention, treatment and care services for people who inject drugs: A systematic review of global, regional, and national coverage. The Lancet, 375, 1014-1028. doi:10.1016/S0140-6736(10)60232-2
69. McCarty, D., Capoccia, V. A.,&Gustafson, D. (2009). Quality improvement for addiction treatment. In R. Ries, D. Fiellin, S. Miller,&R. Saitz (Eds.), Principles of addiction medicine (4th ed., pp. 433-440). New York, NY: Lippincott, Williams&Wilkins.
70. McCarty, D., Capoccia, V. A., Gustafson, D.,&Cotter, F. (2009). Improving care for the treatment of alcohol and drug disorders. Journal of Behavioral Health Services&Research, 36, 52-60. doi:10.1007/ s11414-008-9108-4
71. McCarty, D., Gustafson, D. H., Wisdom, J. P., Ford, J., Choi, D., Molfenter, T., . . . Cotter, F. (2007). The Network for the Improvement of Addiction Treatment (NIATx): Enhancing access and retention. Drug and Alcohol Dependence, 88, 138-145. doi:10.1016/j.drugalcdep .2006.10.009
72. Mental Health Parity and Addiction Equity Act of 2008, Pub. L. No. 110-343, 122 Stat. 3881 (2008).
73. Metsch, L. R., Feaster, D. J., Gooden, L., Matheson, T., Mandler, R. N., Haynes, L., . . . Colfax, G. N. (2012). Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: Results of a randomized trial. American Journal of Public Health, 102, 1160-1167. doi:10.2105/AJPH.2011.300460
74. Metzger, D. S., Woody, G. E., McLellan, A. T., O'Brien, C. P., Druley, P., Navaline, H., . . . Abrutyn, E. (1993). Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 6, 1049-1056.
75. Miller, W. C., Rosenberg, N. E., Rutstein, S. E.,&Powers, K. A. (2010). Role of acute and early HIV infection in the sexual transmission of HIV. Current Opinion in HIV and AIDS, 5, 277-282. doi:10.1097/COH .0b013e32833a0d3a
76. Montaner, J. S. G., Lima, V. D., Barrios, R., Yip, B., Wood, E., Kerr, T., . . . Kendall, P. (2010). Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: A population-based study. The Lancet, 376, 532-539. doi:10.1016/S0140-6736(10)60936-1
77. National Institute on Drug Abuse. (1996). National Institute on Drug Abuse community-based HIV prevention research. Rockville, MD: Author.
78. National Research Council and Institute of Medicine. (1995). Preventing HIV transmission: The role of sterile needles and bleach. Washington, DC: National Academy Press.
79. Needle, R. H., Coyle, S. L., Normand, J., Lambert, E.,&Cesari, H. (1998). HIV prevention with drug-using populations- current status and future prospects: Introduction and overview. Public Health Reports, 113(Suppl. 1), 4-18.
80. Nosyk, B., Guh, D. P., Bansback, N. J., Oviedo-Joekes, E., Brissette, S., Marsh, D. C., . . . Anis, A. H. (2012). Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. Canadian Medical Association Journal, 184(6), E317- E328. doi:10.1503/cmaj.110669
81. Nosyk, B., Guh, D. P., Sun, H., Oviedo-Joekes, E., Brissette, S., Marsh, D. C., . . . Anis, A. H. (2011). Health related quality of life trajectories of patients in opioid substitution treatment. Drug and Alcohol Dependence, 118, 259-264. doi:10.1016/j.drugalcdep.2011.04.003
82. Office of National Drug Control Policy. (2010). National drug control strategy 2010. Washington, DC: Author.
83. Office of National Drug Control Policy. (2011). National drug control strategy 2011. Washington, DC: Author.
84. Oviedo-Joekes, E., Brissette, S., Marsh, D. C., Lauzon, P., Guh, D., Anis, A.,&Schechter, M. T. (2009). Diacetylmorphine versus methadone for the treatment of opioid addiction. New England Journal of Medicine, 361, 777-786. doi:10.1056/NEJMoa0810635
85. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119 (2010). Retrieved from http://www.gpo.gov/fdsys/pkg/ PLAW-111publ148/pdf/PLAW-111publ148.pdf
86. Pollack, H. A.,&D'Aunno, T. (2010). HIV testing and counseling in the nation's outpatient substance abuse treatment system, 1995-2005. Journal of Substance Abuse Treatment, 38, 307-316. doi:10.1016/j.jsat .2009.12.004
87. Prejean, J., Satcher, A. J., Durant, T., Hu, X.,&Lee, L. M. (2006). Racial/ethnic disparities in diagnoses of HIV/AIDS-33 states, 2001- 2004. Morbidity and Mortality Weekly Report (MMWR), 55(05), 121- 125.
88. Ramos, R. (1990). Chicano intravenous drug users. In E. Y. Lambert (Ed.), The collection and interpretation of data from hidden populations (NIDA Research Monograph 98, pp. 128-145). Rockville, MD: National Institute on Drug Abuse.
89. Rehm, J., Gschwend, P., Steffen, T., Gutzwiller, F., Dobler-Mikola, A.,&Uchtenhagen, A. (2001). Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. The Lancet, 358, 1417-1423. doi:10.1016/S0140-6736(01)06529-1
90. Rhodes, F. (1993). The behavioral counseling model for injection drug users: Intervention manual (NIH Publication No. 93-3579). Rockville, MD: National Institute on Drug Abuse.
91. Rosenbaum, M.,&Murphy, S. (1990). Women and addiction: Process, treatment and outcome. In E. Y. Lambert (Ed.), The collection and interpretation of data from hidden populations (NIDA Research Monograph 98, pp. 120-127). Rockville, MD: National Institute on Drug Abuse.
92. Samet, J. H., Friedmann, P. D.,&Saitz, R. (2001). Benefits of linking primary medical care and substance abuse services. Archives of Internal Medicine, 161, 85-91. doi:10.1001/archinte.161.1.85
93. Small, D. (2010). An appeal to humanity: Legal victory in favour of North America's only supervised injection facility: Insite. Harm Reduction Journal, 7, 23. doi:10.1186/1477-7517-7-1
94. Stimson, G. V. (1994). Reconstruction of subregional diffusion of HIV infection among injecting drug users in Southeast Asia: Implications for early intervention. AIDS, 8, 1630 -1632. doi:10.1097/00002030- 199411000-00023
95. Strathdee, S. A., Palepu, A., Cornelisse, P. G. A., Yip, B., O'Shaughnessy, M. V., Montaner, J. S. G., . . . Hogg, R. S. (1998). Barriers to use of free antiretroviral therapy in injection drug users. JAMA: Journal of the American Medical Association, 280, 547-549. doi:10.1001/jama.280.6.547
96. Substance Abuse and Mental Health Services Administration. (2012). Results from the 2011 National Survey on Drug Use and Health: Summary of national findings (NSDUH Series H-44, HHS Publication No. SMA 12-4713). Rockville, MD: Author.
97. Thompson, M. A., Mugavero, M. J., Amico, K. R., Cargill, V. A., Chang, L. W., Gross, R., . . . Nachega, J. B. (2012). Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: Evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Annals of Internal Medicine, 156, 817-833.
98. Tyndall, M. W., Kerr, T., King, E., Montaner, J. S. G.,&Wood, E. (2006). Attendance, drug use patterns, and referrals made from North America's first supervised injection facility. Drug and Alcohol Dependence, 83, 193-198. doi:10.1016/j.drugalcdep.2005.11.011
99. van den Brink, W., Hendriks, V. M.,&van Ree, J. M. (1999). Medical co-prescription of heroin to chronic, treatment-resistant methadone patients in the Netherlands. Journal of Drug Issues, 29, 587-608.
100. Volkow, N. D.,&Montaner, J. (2010). Enhanced HIV testing, treatment, and support for HIV-infected substance users. JAMA: Journal of the American Medical Association, 303, 1423-1424. doi:10.1001/jama.2010.421
101. Volkow, N. D.,&Montaner, J. (2011). The urgency of providing comprehensive and integrated treatment for substance abusers with HIV. Health Affairs, 30, 1411-1419. doi:10.1377/hlthaff.2011.0663
102. Watters, J. K., Estilo, M. J., Clark, G. L.,&Lorvick, K. (1994). Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA: Journal of the American Medical Association, 271, 115-120. doi:10.1001/jama.1994.03510260047027
103. Wechsberg, W. M. (2009). Adapting HIV interventions for women substance abusers in international settings: Lessons for the future. Journal of Drug Issues, 39, 237-243. doi:10.1177/002204260903900120
104. Westergaard, R. P., Ambrose, B. K., Mehta, S. H.,&Kirk, G. D. (2012). Provider and clinic-level correlates of deferring antiretroviral therapy for people who inject drugs: A survey of North American HIV providers. Journal of the International AIDS Society, 15, 1-10. doi:10.1186/ 1758-2652-15-10
105. Wiebel, W. W. (1990). Identifying and gaining access to hidden populations. In E. Y. Lambert (Ed.), The collection and interpretation of data from hidden populations (NIDA Research Monograph 98, pp. 4-11). Rockville, MD: National Institute on Drug Abuse.
106. Wiebel, W. (1993). The indigenous leader outreach model: Intervention manual (NIH Publication No. 93-3581). Rockville, MD: National Institute on Drug Abuse.
107. Wodak, A.,&Cooney, A. (2006). Do needle syringe programs reduce HIV infection among injecting drug users? A comprehensive review of the international evidence. Substance Use&Misuse, 41, 777-813. doi:10.1080/10826080600669579
108. Wood, E., Hogg, R. S., Dias Lima, V., Kerr, T., Yip, B., Marshall, B. D. L.,&Montaner, J. S. G. (2008). Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA: Journal of the American Medical Association, 300, 550-554. doi: 10.1001/jama.300.5.550
109. Wood, E., Kerr, T., Lloyd-Smith, E., Buchner, C., Marsh, D. C., Montaner, J. S. G.,&Tyndall, M. W. (2004). Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. Harm Reduction Journal, 1, 9. doi:10.1186/1477- 7517-1-9
110. Wood, E., Tyndall, M. W., Spittal, P. M., Li, K., Hogg, R. S., O'Shaughnessy, M. V.,&Schechter, M. T. (2002). Needle exchange and difficulty with needle access during an ongoing HIV epidemic. International Journal of Drug Policy, 13, 95-102. doi:10.1016/S0955- 3959(02)00008-7
111. Wood, E., Werb, D., Kazatchkine, M., Kerr, T., Hankins, C., Gorna, R., . . . Montaner, J. (2010). Vienna Declaration: A call for evidence-based drug policies. The Lancet, 376, 310 -312. doi:10.1016/S0140- 6736(10)60958-0